The Potential Role of Nitric Oxide in Cardiovascular Safety When Treating Patients with Osteoarthritis and Hypertension: A Moderated Panel Discussion
To access this article, please choose from the options below
As of time of publication, rofecoxib has been removed from the market by the manufacturer.
Statement of author disclosure: Please see the Author Disclosures section at the end of this article.
PII: S0002-9343(09)00209-5
doi:10.1016/j.amjmed.2009.03.005
© 2009 Elsevier Inc. All rights reserved.

